Terms: = Prostate cancer AND CDK12, KIAA0904, CRKRS, 51755, ENSG00000167258, CRK7, CRKR, Q9NYV4 AND Treatment
52 results:
1. Cyclin-dependent kinase 12 deficiency reprogrammes cellular metabolism to alleviate ferroptosis potential and promote the progression of castration-resistant prostate cancer.
Zhang H; Zhou Y; Feng Y; Hou W; Chen Y; Xing Z; Zhang Y; Wei Q; Yin Y; Guo J; Hu H
Clin Transl Med; 2024 May; 14(5):e1678. PubMed ID: 38736108
[TBL] [Abstract] [Full Text] [Related]
2. Exploring the tumor genomic landscape of aggressive prostate cancer by whole-genome sequencing of tissue or liquid biopsies.
Weiss S; Lamy P; Rusan M; Nørgaard M; Ulhøi BP; Knudsen M; Kassentoft CG; Farajzadeh L; Jensen JB; Pedersen JS; Borre M; Sørensen KD
Int J Cancer; 2024 Jul; 155(2):298-313. PubMed ID: 38602058
[TBL] [Abstract] [Full Text] [Related]
3. Development of Novel Models of Aggressive Variants of Castration-resistant prostate cancer.
Bigot L; Sabio J; Poiraudeau L; Annereau M; Menssouri N; Helissey C; Déas O; Aglave M; Ibrahim T; Pobel C; Nobre C; Nicotra C; Ngo-Camus M; Lacroix L; Rouleau E; Tselikas L; Judde JG; Chauchereau A; Bernard-Tessier A; Patrikidou A; Naoun N; Flippot R; Colomba E; Fuerea A; Albiges L; Lavaud P; Massard C; Friboulet L; Fizazi K; Besse B; Scoazec JY; Loriot Y
Eur Urol Oncol; 2024 Jun; 7(3):527-536. PubMed ID: 38433714
[TBL] [Abstract] [Full Text] [Related]
4. treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes.
Olmos D; Lorente D; Alameda D; Cattrini C; Romero-Laorden N; Lozano R; Lopez-Casas PP; Jambrina A; Capone C; Vanden Broecke AM; Trevisan M; Van Sanden S; Jürgens A; Herrera-Imbroda B; Castro E
Ann Oncol; 2024 May; 35(5):458-472. PubMed ID: 38417742
[TBL] [Abstract] [Full Text] [Related]
5. cdk12 regulates angiogenesis of advanced prostate cancer by IGFBP3.
Zhong K; Luo W; Li N; Tan X; Li Y; Yin S; Huang Y; Fang L; Ma W; Cai Y; Yin Y
Int J Oncol; 2024 Feb; 64(2):. PubMed ID: 38186306
[TBL] [Abstract] [Full Text] [Related]
6. DNA Damage Response and Mismatch Repair Gene Defects in Advanced and Metastatic prostate cancer.
Akhoundova D; Francica P; Rottenberg S; Rubin MA
Adv Anat Pathol; 2024 Mar; 31(2):61-69. PubMed ID: 38008971
[TBL] [Abstract] [Full Text] [Related]
7. Inhibition of the Cyclin K-cdk12 complex induces DNA damage and increases the effect of androgen deprivation therapy in prostate cancer.
Frei K; Schecher S; Daher T; Hörner N; Richter J; Hildebrand U; Schindeldecker M; Witzel HR; Tsaur I; Porubsky S; Gaida MM; Roth W; Tagscherer KE
Int J Cancer; 2024 Mar; 154(6):1082-1096. PubMed ID: 37916780
[TBL] [Abstract] [Full Text] [Related]
8. Comprehensive genomic profiling testing in Japanese castration-resistant prostate cancer patients: results of a single-center retrospective cohort study.
Fukushima T; Goto K; Hayashi T; Ikeda K; Hatayama T; Yamanaka R; Iwane K; Tasaka R; Kohada Y; Takemoto K; Kobatake K; Goriki A; Toshida A; Nakahara H; Motonaga M; Tokumo K; Fujii Y; Hayes CN; Okamoto W; Kubo T; Matsumoto T; Shiota M; Yamamoto N; Urabe Y; Hiyama E; Arihiro K; Hinoi T; Hinata N
Jpn J Clin Oncol; 2024 Feb; 54(2):175-181. PubMed ID: 37899139
[TBL] [Abstract] [Full Text] [Related]
9. Prediction of Resistance to
Sartor O; Ledet E; Huang M; Schwartz J; Lieberman A; Lewis B; Layton J; Barata P; Jang A; Hawkins M; Pocha O; Lanka S; Harris K
J Nucl Med; 2023 Nov; 64(11):1721-1725. PubMed ID: 37770113
[No Abstract] [Full Text] [Related]
10. Rucaparib for the treatment of Metastatic Castration-resistant prostate cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study.
Abida W; Campbell D; Patnaik A; Bryce AH; Shapiro J; Bambury RM; Zhang J; Burke JM; Castellano D; Font A; Ganju V; Hardy-Bessard AC; McDermott R; Sautois B; Spaeth D; Voog E; Piulats JM; Pintus E; Ryan CJ; Merseburger AS; Daugaard G; Heidenreich A; Fizazi K; Loehr A; Despain D; Simmons AD; Dowson M; Go J; Watkins SP; Chowdhury S
Eur Urol; 2023 Sep; 84(3):321-330. PubMed ID: 37277275
[TBL] [Abstract] [Full Text] [Related]
11. Early Plasma Circulating Tumor DNA as a Potential Biomarker of Disease Recurrence in Non-metastatic prostate cancer.
Fei X; Du X; Gong Y; Liu J; Fan L; Wang J; Wang Y; Zhu Y; Pan J; Dong B; Xue W
Cancer Res Treat; 2023 Jul; 55(3):969-977. PubMed ID: 36915250
[TBL] [Abstract] [Full Text] [Related]
12. Pan-cancer association of DNA repair deficiencies with whole-genome mutational patterns.
Sørensen SG; Shrikhande A; Poulsgaard GA; Christensen MH; Bertl J; Laursen BE; Hoffmann ER; Pedersen JS
Elife; 2023 Mar; 12():. PubMed ID: 36883553
[TBL] [Abstract] [Full Text] [Related]
13. Homologous recombination repair gene mutations in Malaysian prostate cancer patients.
Saeidi H; Raju CS; Ismail P; Raub SHA; Omar N; Hisyam Bakrin I
Cell Mol Biol (Noisy-le-grand); 2022 Aug; 68(8):22-26. PubMed ID: 36800845
[TBL] [Abstract] [Full Text] [Related]
14. A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant prostate cancer (mCRPC) with Bone Metastases (COMRADE).
Pan E; Xie W; Ajmera A; Araneta A; Jamieson C; Folefac E; Hussain A; Kyriakopoulos CE; Olson A; Parikh M; Parikh R; Saraiya B; Ivy SP; Van Allen EM; Lindeman NI; Kochupurakkal BS; Shapiro GI; McKay RR
Mol Cancer Ther; 2023 Apr; 22(4):511-518. PubMed ID: 36780008
[TBL] [Abstract] [Full Text] [Related]
15. The prevalence of gene mutations in homologous recombination repair pathways in Japanese patients with metastatic castration-resistant prostate cancer in real-world clinical practice: The multi-institutional observational ZENSHIN study.
Uemura H; Oya M; Kamoto T; Sugimoto M; Shinozaki K; Morita K; Koto R; Takahashi M; Nii M; Shin E; Nonomura N
Cancer Med; 2023 Mar; 12(5):5265-5274. PubMed ID: 36358026
[TBL] [Abstract] [Full Text] [Related]
16. MAPK8IP2 is a potential prognostic biomarker and promote tumor progression in prostate cancer.
Zeng Z; He W; Jiang Y; Jiang H; Cheng X; Deng W; Zhou X; Zhang C; Wang G
BMC Cancer; 2022 Nov; 22(1):1162. PubMed ID: 36357836
[TBL] [Abstract] [Full Text] [Related]
17. Molecular Genetics of prostate cancer and Role of Genomic Testing.
Akhoundova D; Feng FY; Pritchard CC; Rubin MA
Surg Pathol Clin; 2022 Dec; 15(4):617-628. PubMed ID: 36344179
[TBL] [Abstract] [Full Text] [Related]
18. CYCLIN K down-regulation induces androgen receptor gene intronic polyadenylation, variant expression and PARP inhibitor vulnerability in castration-resistant prostate cancer.
Sun R; Wei T; Ding D; Zhang J; Chen S; He HH; Wang L; Huang H
Proc Natl Acad Sci U S A; 2022 Sep; 119(39):e2205509119. PubMed ID: 36129942
[TBL] [Abstract] [Full Text] [Related]
19. Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic prostate cancer Following Progression on Androgen-Targeting Therapies.
Zurita AJ; Graf RP; Villacampa G; Raskina K; Sokol E; Jin D; Antonarakis ES; Li G; Huang RSP; Casanova-Salas I; Vivancos A; Carles J; Ross JS; Schrock AB; Oxnard GR; Mateo J
JCO Precis Oncol; 2022 Jul; 6():e2200195. PubMed ID: 35820087
[TBL] [Abstract] [Full Text] [Related]
20. Targeting signaling pathways in prostate cancer: mechanisms and clinical trials.
He Y; Xu W; Xiao YT; Huang H; Gu D; Ren S
Signal Transduct Target Ther; 2022 Jun; 7(1):198. PubMed ID: 35750683
[TBL] [Abstract] [Full Text] [Related]
[Next]